m6A-centered Disease Response Information

General Information of the Disease (ID: M6ADIS0167)
Name
Lupus erythematosus
ICD
ICD-11: 4A40
Full List of Target Gene(s) of This m6A-centered Disease Response
TNF alpha-induced protein 3 (TNFAIP3)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [1]
Response Summary MiR-19a regulated TNF alpha-induced protein 3 (TNFAIP3) degradation by downregulating the expression of YTH N6-methyladenosine RNA-binding protein 2 (YTHDF2). The circGARS sponges miR-19a to regulate YTHDF2 expression to promote SLE progression through the A20/NF-Kappa-B axis and acts as an independent biomarker to help the treatment of SLE patients.
Responsed Disease Lupus erythematosus [ICD-11: 4A40]
Target Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
Target Regulation Up regulation
Cell Process Immunity
In-vitro Model PBMCs (Human peripheral blood mononuclear cells (PBMCs) are isolated from peripheral blood and identified as any blood cell with a round nucleus)
References
Ref 1 N6-methyladenosine-dependent modification of circGARS acts as a new player that promotes SLE progression through the NF-KappaB/A20 axis. Arthritis Res Ther. 2022 Feb 4;24(1):37. doi: 10.1186/s13075-022-02732-x.
Ref 2 Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73. doi: 10.1016/j.bmcl.2010.06.145. Epub 2010 Jul 23.
Ref 3 Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17.